Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...
Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...
8h
Zacks.com on MSNPCRX Doses First Patient in Phase II PCRX-201 Gene Therapy StudyPacira BioSciences PCRX announced that it has dosed the first patient in a mid-stage study of pipeline candidate PCRX-201 ...
Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...
Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
1d
Pharmaceutical Technology on MSNAtsena closes $150m in Series C round to progress gene therapyAtsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ...
The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...
None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results